Skip to main content
. 2024 Dec 12;19(12):e0315287. doi: 10.1371/journal.pone.0315287

Fig 2.

Fig 2

Meta-analysis showing, among all BC cases (HER2 IHC 0, 1+, 2+/ISH-, 2+/ISH+, and 3+), the prevalence of HER2-zero (a), HER2-low (b), and HER2-positive expressing tumors.